Literature DB >> 11781352

Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis.

Shereen Ezzat1, Lei Zheng, Xian-Feng Zhu, Gillian E Wu, Sylvia L Asa.   

Abstract

It is estimated that up to one in five individuals develop pituitary gland tumors. Despite the common occurrence of these tumors, the pathogenetic mechanisms underlying their development remain largely unknown. We report the identification of a novel pituitary tumor-derived, N-terminally truncated isoform of FGF receptor-4 (ptd-FGFR4). The corresponding mRNA results from alternative transcription initiation and encodes a polypeptide that lacks a signal peptide and the first two extracellular Ig-like domains. ptd-FGFR4 has a distinctive cytoplasmic residence, is constitutively phosphorylated, and is transforming in vitro and in vivo. Here we show that targeted expression of ptd-FGFR4, but not FGFR4, results in pituitary tumors that morphologically recapitulate the human disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11781352      PMCID: PMC150823          DOI: 10.1172/JCI14036

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  33 in total

1.  Identification of a novel alternative splicing of human FGF receptor 4: soluble-form splice variant expressed in human gastrointestinal epithelial cells.

Authors:  S Takaishi; M Sawada; Y Morita; H Seno; H Fukuzawa; T Chiba
Journal:  Biochem Biophys Res Commun       Date:  2000-01-19       Impact factor: 3.575

2.  Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas.

Authors:  L Vallar; A Spada; G Giannattasio
Journal:  Nature       Date:  1987 Dec 10-16       Impact factor: 49.962

Review 3.  The cytogenesis and pathogenesis of pituitary adenomas.

Authors:  S L Asa; S Ezzat
Journal:  Endocr Rev       Date:  1998-12       Impact factor: 19.871

4.  Expression and glycosylation studies of human FGF receptor 4.

Authors:  H Tuominen; P Heikinheimo; B M Loo; K Kataja; C Oker-Blom; M Uutela; M Jalkanen; A Goldman
Journal:  Protein Expr Purif       Date:  2001-03       Impact factor: 1.650

Review 5.  Structural characterization and biological functions of fibroblast growth factor.

Authors:  D Gospodarowicz; N Ferrara; L Schweigerer; G Neufeld
Journal:  Endocr Rev       Date:  1987-05       Impact factor: 19.871

6.  Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis.

Authors:  A P Heaney; G A Horwitz; Z Wang; R Singson; S Melmed
Journal:  Nat Med       Date:  1999-11       Impact factor: 53.440

7.  Pituitary lactotroph adenomas develop after prolonged lactotroph hyperplasia in dopamine D2 receptor-deficient mice.

Authors:  S L Asa; M A Kelly; D K Grandy; M J Low
Journal:  Endocrinology       Date:  1999-11       Impact factor: 4.736

8.  Fibroblast growth factor receptor-4 splice variants cause deletion of a critical tyrosine.

Authors:  W R van Heumen; C Claxton; J O Pickles
Journal:  IUBMB Life       Date:  1999-07       Impact factor: 3.885

9.  A soluble dominant negative fibroblast growth factor receptor 4 isoform in human MCF-7 breast cancer cells.

Authors:  S Ezzat; L Zheng; S Yu; S L Asa
Journal:  Biochem Biophys Res Commun       Date:  2001-09-14       Impact factor: 3.575

10.  Heterogenous in vivo and in vitro expression of basic fibroblast growth factor by human pituitary adenomas.

Authors:  S Ezzat; H S Smyth; L Ramyar; S L Asa
Journal:  J Clin Endocrinol Metab       Date:  1995-03       Impact factor: 5.958

View more
  39 in total

1.  Pituitary adenomas in man and mouse: oncogenic potential of a truncated fibroblast growth factor receptor 4.

Authors:  Malcolm J Low
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

2.  Persistent ERK/MAPK activation promotes lactotrope differentiation and diminishes tumorigenic phenotype.

Authors:  Allyson Booth; Tammy Trudeau; Crystal Gomez; M Scott Lucia; Arthur Gutierrez-Hartmann
Journal:  Mol Endocrinol       Date:  2014-12

Review 3.  Pathogenesis of pituitary tumors.

Authors:  Shlomo Melmed
Journal:  Nat Rev Endocrinol       Date:  2011-03-22       Impact factor: 43.330

4.  Loss of heterozygosity and DNA methylation affect germline fibroblast growth factor receptor 4 polymorphism to direct allelic selection in breast cancer.

Authors:  Xuegong Zhu; Lei Zheng; Sylvia L Asa; Shereen Ezzat
Journal:  Am J Pathol       Date:  2010-10-29       Impact factor: 4.307

Review 5.  Pathogenesis of prolactinomas.

Authors:  Anna Spada; Giovanna Mantovani; Andrea Lania
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

6.  Pituitary somatolactotropes evade an oncogenic response to Ras.

Authors:  Allyson K Roof; Tammy Trudeau; Arthur Gutierrez-Hartmann
Journal:  Mol Cell Endocrinol       Date:  2018-05-09       Impact factor: 4.102

7.  The role of mediators of cell invasiveness, motility, and migration in the pathogenesis of silent corticotroph adenomas.

Authors:  Ozgur Mete; Caroline Hayhurst; Hussein Alahmadi; Eric Monsalves; Hasan Gucer; Fred Gentili; Shereen Ezzat; Sylvia L Asa; Gelareh Zadeh
Journal:  Endocr Pathol       Date:  2013-12       Impact factor: 3.943

Review 8.  Clinical and molecular genetics of acromegaly: MEN1, Carney complex, McCune-Albright syndrome, familial acromegaly and genetic defects in sporadic tumors.

Authors:  Anelia Horvath; Constantine A Stratakis
Journal:  Rev Endocr Metab Disord       Date:  2008-03       Impact factor: 6.514

9.  Ikaros isoforms in human pituitary tumors: distinct localization, histone acetylation, and activation of the 5' fibroblast growth factor receptor-4 promoter.

Authors:  Shereen Ezzat; Shunjiang Yu; Sylvia L Asa
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

Review 10.  Mechanisms for pituitary tumorigenesis: the plastic pituitary.

Authors:  Shlomo Melmed
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.